Heart Failure
Conditions
Brief summary
It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedance-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.
Interventions
DEVICELung Impedance-Guided Therapy
Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
Sponsors
Hillel Yaffe Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
In this study the interventional group was treated preemptively according to the lung-impedance protocol and the control group was treated only according to clinical assessment.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure
Exclusion criteria
* Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevention of acute heart failure development in acute MI patients | Three years |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of clinical outcome in patients with lung impedance-guided treatments | Three years |
Countries
Israel
Outcome results
None listed